-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Private Companies Account for 36% of Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Ownership, While Individual Investors Account for 29%
Private Companies Account for 36% of Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Ownership, While Individual Investors Account for 29%
Every investor in Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are private companies with 36% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And individual investors on the other hand have a 29% ownership in the company.
Let's take a closer look to see what the different types of shareholders can tell us about Shanghai Pharmaceuticals Holding.
See our latest analysis for Shanghai Pharmaceuticals Holding
SHSE:601607 Ownership Breakdown August 30th 2022What Does The Institutional Ownership Tell Us About Shanghai Pharmaceuticals Holding?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Shanghai Pharmaceuticals Holding already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Shanghai Pharmaceuticals Holding, (below). Of course, keep in mind that there are other factors to consider, too.
SHSE:601607 Earnings and Revenue Growth August 30th 2022Hedge funds don't have many shares in Shanghai Pharmaceuticals Holding. SIIC Shanghai (Holdings) Co.,Ltd. is currently the company's largest shareholder with 30% of shares outstanding. In comparison, the second and third largest shareholders hold about 18% and 4.5% of the stock.
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Shanghai Pharmaceuticals Holding
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our information suggests that Shanghai Pharmaceuticals Holding Co., Ltd insiders own under 1% of the company. But they may have an indirect interest through a corporate structure that we haven't picked up on. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own CN¥1.5m worth of shares. Arguably recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 29% stake in Shanghai Pharmaceuticals Holding. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
We can see that Private Companies own 36%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Public Company Ownership
We can see that public companies hold 18% of the Shanghai Pharmaceuticals Holding shares on issue. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Shanghai Pharmaceuticals Holding better, we need to consider many other factors. Take risks for example - Shanghai Pharmaceuticals Holding has 3 warning signs we think you should be aware of.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
上海医药控股有限公司(上海证券交易所代码:601607)的每一位投资者都应该知道最强大的股东群体。而持有这块蛋糕最大份额的是拥有36%股权的私营公司。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
另一方面,个人投资者拥有该公司29%的股份。
让我们仔细看看不同类型的股东对上海医药控股有什么启示。
查看我们对上海医药控股的最新分析
上海证交所:601607所有权明细2022年8月30日关于上海医药控股,机构持股告诉了我们什么?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
上海医药控股已有登记在册的机构。事实上,他们在该公司拥有可观的股份。这意味着为这些机构工作的分析师已经看过了这只股票,他们喜欢它。但就像其他人一样,他们也可能错了。如果两个大型机构投资者试图同时抛售一只股票,股价大幅下跌的情况并不少见。因此,值得查看上海医药控股过去的盈利轨迹(见下图)。当然,请记住,还有其他因素需要考虑。
上海证交所:601607收益和收入增长2022年8月30日对冲基金在上海医药控股的股份并不多。上汽上海(控股)有限公司目前是该公司的第一大股东,持有30%的流通股。相比之下,第二大和第三大股东分别持有约18%和4.5%的股份。
经过进一步挖掘,我们发现,前3名股东合计控制了公司一半以上的股份,这意味着他们拥有相当大的权力来影响公司的决策。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。相当多的分析师追踪这只股票,所以你可以很容易地研究预测增长。
上海医药控股的内部人持股
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。管理层最终要向董事会负责。然而,经理人担任执行董事会成员并不少见,尤其是如果他们是创始人或首席执行官的话。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
我们的信息显示,上海医药控股有限公司内部人士持有该公司不到1%的股份。但他们可能通过一种我们没有注意到的公司结构拥有间接利益。由于它是一家大公司,我们预计内部人士只会持有它一小部分股份。但值得注意的是,他们持有价值150万元人民币的股票。可以说,最近的买入和卖出也同样重要。你可以点击这里,看看内部人士是在买入还是卖出。
一般公有制
普通公众通常是个人投资者,他们持有上海医药控股29%的股份。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私营公司所有权
我们可以看到,私营公司拥有36%的已发行股份。仅从这一事实很难得出任何结论,因此值得调查一下谁拥有这些私营公司。有时,内部人士或其他关联方通过一家独立的私人公司拥有上市公司的股份。
上市公司所有权
我们可以看到,上市公司持有上海医药发行股份的18%。很难说肯定,但这表明他们的商业利益交织在一起。这可能是一个战略利害关系,因此值得关注这一所有权变化的空间。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但要更好地理解上海医药控股,我们还需要考虑许多其他因素。以风险为例-上海医药控股有限公司3个警示标志我们认为你应该意识到。
如果你像我一样,你可能会想一想这家公司是会增长还是会萎缩。幸运的是,您可以查看这份显示分析师对其未来预测的免费报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧